Celldex Couldn’t Sway FDA On Rintega
This article was originally published in The Pink Sheet Daily
Executive Summary
Although it yielded impressive survival data compared to standard of care, the Phase II ReACT study was not powered for efficacy, so FDA is requiring Phase III data as well despite the need in glioblastoma.